- Home
- ARR vs AGIO Comparison
ARR vs AGIO Comparison
Compare ARR & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARR | AGIO |
|---|---|---|
| Founded | 2008 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.3B |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | ARR | AGIO |
|---|---|---|
| Price | $16.27 | $36.36 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 8 |
| Target Price | $18.50 | ★ $38.88 |
| AVG Volume (30 Days) | ★ 4.5M | 1.1M |
| Earning Date | 04-22-2026 | 04-29-2026 |
| Dividend Yield | ★ 16.69% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $43,011,000.00 |
| Revenue This Year | N/A | $76.75 |
| Revenue Next Year | N/A | $170.73 |
| P/E Ratio | $27.18 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.98 | $22.24 |
| 52 Week High | $19.31 | $46.00 |
Technical Indicators
Market Signals| Indicator | ARR | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 37.77 | 47.03 |
| Support Level | $15.31 | $26.71 |
| Resistance Level | $17.72 | $44.51 |
| Average True Range (ATR) | 0.34 | 1.85 |
| MACD | -0.09 | -0.87 |
| Stochastic Oscillator | 23.91 | 13.39 |
Price Performance
Historical ComparisonAbout ARR ARMOUR Residential REIT Inc.
ARMOUR Residential REIT Inc operate in the U.S. and invest in fixed rate residential, adjustable rate and hybrid adjustable rate residential MBS issued or guaranteed by U.S. GSEs or guaranteed by Ginnie Mae. It also invest in U.S. Treasury Securities and money market instruments.
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.